

Iris Agreiter

Mater Misericordiae University Hospital | Ireland

Diana Averbukh

Faculty of Medicine, Hebrew University of Jerusalem, Hadassah Medical Center, Jerusalem | Israel

Dr. Dina Averbuch is a Head of Paediatric Infectious Diseases Unit in Hadassah University Hospital in Jerusalem, Israel. Her research primarily concerns infections in immune-compromised hosts — in patients with cancer, following hematopoietic stem cell transplantation (HSCT), and in children with primary immune deficiencies. She participates in the European Conference of Infections in Leukaemia group (ECIL); and she is a Secretary of Infectious Diseases Working Party (IDWP) of the EBMT. She authored and co-authored 100 manuscripts including original articles, international guidelines and reviews; and chapters in five books; with a total of 3838 citations; H index 27. She led several international studies within the EBMT, including study of antimicrobial resistance among Gram-negative rods, nocardiosis and listeriosis in HCT patients.

Adriana Cristina Balduzzi

Clinica Pediatrica Università degli Studi Milano Bicocca | Italy

Adriana Balduzzi works as an Associate Professor of Paediatrics at the Clinica Pediatrica Università degli Studi di Milano Bicocca in Monza, Italy. She is in charge of the Transplantation Unit and of the CAR-T cell clinical program.

Since the year 2009 Adriana Balduzzi has been an active member of the Board of the Paediatric Diseases Working Party of the EBMT, since 2015 the Chairman of the SCT Committee of the I-BFM SG and since 2020 a founding member of the Paediatric Scientific Working Group of the EHA.

She is the principal investigator of the EU FORTEe Project in Monza (funded from the European Union's Horizon 2020 research and innovation programme, under grant agreement No 945153), which promotes precision exercise in haemato-oncological patients.

Anna Barata

Massachusetts General Hospital Cancer Center and Harvard Medical School | United States of America

She graduated in Psychology (Universitat Ramon Llull, Barcelona), received a Master in Psycho-Oncology (Universidad Complutense de Madrid) and earned a PhD in Psychiatry and Medical Psychology (Universitat Autònoma de Barcelona). She completed a postdoctoral fellowship in behavioral oncology at the Moffitt Cancer Center (Tampa, FL).

Abdulhamid Bazarbachi

Jacobi Medical Center, Albert Einstein College of Medicine | United States of America

Dr Abdul-Hamid Bazarbachi is currently a third-year Internal Medicine resident at Jacobi Medical Center affiliated with the Albert Einstein College of Medicine, NYC, NY, and is pursuing a career in malignant haematology and cellular therapy. Much of Dr AH Bazarbachi's clinical research is focused on stem-cell transplantation in acute leukaemia's, genomics and transcriptomics, and novel therapies in multiple myeloma. Dr AH Bazarbachi obtained his medical degree from the American University of Beirut, Lebanon, before completing a post-doctoral at the Haematology and Cellular Therapy Department at the Saint-Antoine Hospital at the University Pierre & Marie Curie, Paris, France, followed by a post-doctoral at the Medical Oncology and Data Science departments at the Dana-Farber Cancer Institute, Boston, MA. Dr AH Bazarbachi has published widely in the field of stem-cell transplantation, leukaemia, and myeloma, and serves as a regular reviewer in different immunology, haematology, and cancer journals.

Didier Blaise

Institute Paoli Calmettes | France

Donor selection Professor Blaise was a founding member of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), a former president of this society and active member of numerous international scientific societies and notably EBMT, EHA, ASH, ASCO ASTCT, ISEH. His research interests focus on clinical transplantation, dose intensity of conditioning regimens, immunomodulation after allogeneic transplantation, immunotherapy and cellular immunotherapy of hematologic malignancies and solid tumours, and the economic and social impact of innovation. His medical interest focuses on the introduction of innovation in these areas.

Nicolas Boissel

Saint-Louis Hospital | France

Nicolas Boissel is Head of the Adolescent and Young Adults Unit at Saint-Louis Hospital in Paris (France) and the chairman of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). His research topics include risk stratification and new therapeutic approaches in acute leukaemia, with a focus on immunotherapy.

Eolia Brissot

Saint-Antoine Hospital, APHP | France

Eolia Brissot, MD, PhD, is Associate- Professor of Haematology and works at Haematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). She attended the University of Nantes, France, where she completed her medical degree. She then undertook a PhD at Sorbonne University in Paris, before working at the laboratory of hematologic stem cell transplantation unit at the NIH, Bethesda, USA. She is also Secretary of the ALWP of the European Society for Blood and Marrow Transplantation (EBMT). She has a special clinical and research focus on the development of GVHD prophylaxis, immunotherapy and different aspects of therapy of ALL.

Maria Dolores Caballero

Hospital Universitario de Salamanca | Spain

Head of Clinical, Transplant and CART Unit, haematology department Salamanca, Spain.

Full professor of Medicine, Salamanca University. IBSAL Transplant and Cell therapy Group (Instituto Biosanitario de Salamanca) President of GELTAMO Foundation. Interest areas: Transplant and Lymphoma

Luca Castagna

Ospedale Villa Sofia-Cervello, Palermo | Italy

Dr Luca Castagna is actually the Chief of the Transplantation program in the Ospedale Cervello, (Palermo, Italy). Graduated at the University of L'Aquila, he had a postgraduate degree in Oncology at the University of Chieti (Italy) in and Hematology at Milan University (Italy). Dr Castagna spent many years in the Haematology Department of Institut Gustave Roussy (Paris, France), as a senior assistant. More recently, he co-worked actively with the Bone Marrow Unit of Institut Paoli Calmettes (Marseille, France), to the development of a new and more adapted conditioning regimen. In the last years, his research has been focused on haploidentical transplantation using T-replete bone marrow and post-infusion cyclophosphamide in patients with advanced Hodgkin's and non-Hodgkin's lymphoma.

Simone Cesaro

Paediatric Haematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona | Italy

Graduated in Medicine and specialized in Paediatrics at the University of Padua, from 2009, I took the Direction of the Paediatric Haematology and Oncology Unit at the Department of Mother and Child of Verona, Italy. From 2010 to 2016, I was the Chairman of Infectious Diseases Working Party of European Society for Blood and Marrow Transplantation, and, from 2015, I am the chairman of the Infectious Diseases and Supportive Therapy Working Group of Italian Association of Paediatric Haematology Oncology. My clinical research includes more than 300 publications in peer-reviewed journals. I obtained the Italian qualification of Associate Professor of Paediatrics in 2016 and of Full Professor of Paediatrics in 2018, released by MIUR (Ministry of Education, University and Research. Italy).

Christian Chabannon

Institut Paoli-Calmettes | France

Head & Qualified person, Centre de Thérapie Cellulaire (Cell Collection & Cell Processing facilities), Institut Paoli-Calmettes Comprehensive Cancer Centre, Marseille, France. Professor of Medicine in Cell Biology, Aix-Marseille Université School of Medicine. Formerly Chair of the EBMT Cellular Therapy & Immunobiology Working Party.

Fabio Ciceri

IRCCS Ospedale San Raffaele Milano | Italy

Fabio Ciceri, MD, graduated in Medicine at University of Pavia (1989), received Board certification of Rheumatology (1995) and Haematology (2001). He is Director of Haematology and Bone Marrow Transplantation Unit at San Raffaele Scientific Institute in Milano, Italy. He is Full Professor of Haematology at University Vita-Salute San Raffaele. He is President of GITMO (Gruppo Italiano Trapianto Midollo). He is Director of Stem Cell Programme at San Raffaele Scientific Institute. He is co-investigator in gene therapy for genetic disorders and Principal Investigator in cell&gene therapy. His research interests include stem cell transplantation for haemato-oncology, inherited disorders and autoimmune diseases.

Ruth Clout

The Christie NHS Foundation Trust | United Kingdom

I am the senior clinical practice facilitator for the haematology, transplant and TYA service at the Christie Hospital in Manchester. I have worked in the speciality for 22 years, in both inpatient and outpatient haematology and transplant. For the past 10 years, I have worked in an education role. I have recently taken on the nurse's role in the CTIWP working party.

Josu de la Fuente

Imperial College London | United Kingdom

Josu de la Fuente is a Consultant Haematologist at Imperial College Healthcare NHS Trust and Professor of Practice (Cellular and Gene Therapies) of Imperial College London. He was appointed Director of the Paediatric Blood & Marrow Transplant Programme in 2006, specialising in transplantation for haemoglobinopathies and bone marrow failure, and being innovative in the use of alternative donors. He is the vice-chair of the Paediatric Diseases Working Party of EBMT, a member of the steering committee of the BMT CTN 1507 trial Co-Director of the Vanderbilt Global Consortium for a Cure. He is an investigator and in the steering committee of several gene therapy trials in sickle cell disease and thalassaemia.

Harry Dolstra

Radboudumc | Netherlands

Harry Dolstra received his Master's degree from the University of Utrecht in 1993 in Molecular-Cellular Biology. He then received his doctorate (cum laude) from the University of Nijmegen in 1999. The topic of his thesis was "Donor cytotoxic T cell responses against leukaemia in allogeneic bone marrow recipients". He completed his post-doctorate work at the Radboud University Medical Center and the CRC for Cancer studies in Birmingham, UK. In 2015 he became Associate Professor and in 2017 Head of the Cell Therapy Facility at the Radboud University Medical Center, where he continues to date. His research in the field of "Translational Immunohematology" is centred on the immunobiology of graft-versus-tumour responses after allogeneic hematopoietic stem cell transplantation and the development of innovative complementary (cellular) immunotherapy against cancer.

Joanna Drozd-Sokołowska

Central Clinical Hospital, Medical University of Warsaw | Poland

Joanna Drozd-Sokolowska is a haematologist at the Medical University of Warsaw. She is involved in the research conducted by CMWP of the EBMT, where she serves as secretary and Polish scientific societies of PALG, PLRG, and PMG. Her special interests are myelodysplastic and lymphoid neoplasms.

Carlo Dufour

IRCCS G. Gaslini Children's Hospital | Italy

Carlo Dufour works in G.Gaslini Research Children's Hospital, Genova, Italy, the largest, multi-specialist paediatric hospital of the country, where he chairs the Hemo-Onco- HSCT Department and the Haematology Unit. In December 2019 he was awarded for scientific contribution in Fanconi Anemia by the Spanish "Fundación la Anemia de Fanconi". In August 2020 he has been awarded by the EBMT along with Prof Regis Peffault de Latour and Prof Antonio Risitano, with the Van Bekkum award, a recognition reserved to best scientific communication of the year, as Co PI of the prospective randomized trial RACE (Comparison of classical IST ± Eltombopag) in Severe Aplastic Anaemia.

Maria Schou Ebbesen

Copenhagen University Hospital Rigshospitalet | Denmark

Medical doctor and post.doc researcher. Research work concerning acute toxicities following HSCT especially in paediatric patients and how the toxicities relate to gut barrier disruption and protective factors hereof

Seçkin Erdal

Acibadem Altunizade Hastanesi | Turkey

Mrs. Seçkin Erdal started nursing profession in 1980. In 1989, she worked as a nurse in charge at Adult Bone Marrow Transplantation Unit in Marmara University Hospital, in Istanbul. Mrs. Erdal retired from her university position in 2006 and continued as a nurse in charge of private health institutions.

In 2015, she was appointed as a local nurse at the 41st EBMT annual meeting held in Istanbul. Mrs. Erdal established the EBMT Turkey nurses group and she took on the task of group president during the same year.

Mrs. Erdal is still the main board member of the Turkey EBMT Nurses Group and the nurse in charge of the Adult Bone Marrow Transplantation Unit at Altunizade Acibadem Hospital in Istanbul, Turkey.

Carlos Fernández de Larrea

Hospital Clínic de Barcelona | Spain

Carlos Fernández de Larrea, MD, PhD, is currently a medical staff (Consultor) of the Department of Haematology and member of the Amyloidosis and Myeloma Unit at Hospital Clínic de Barcelona, junior group leader at IDIBAPS and Associate Professor of Medicine in the University of Barcelona.

Nico Gagelmann

University Medical Center Hamburg-Eppendorf | Germany

Medical School Hamburg from 2014-2020. Resident trainee at University Medical Center Hamburg-Eppendorf, Department of Stem Cell Transplantation, Prof. Kröger

Co-Chair EBMT Trainee Committee

EBMT-CMWP subcommittee chair CAR-T for plasma cell disorders

Fernando González Candelas

University of Valencia – FISABIO | Spain

Professor of Genetics, with extensive research in molecular epidemiology and evolution of bacterial and viral pathogens, based on the analysis of complete genome sequences. For this, I work regularly in the intersection of genomics, bioinformatics, high-throughput sequencing, molecular evolution and population genetics.

Raffaella Greco

IRCCS San Raffaele Hospital | Italy

Haematologist deeply involved in hematopoietic stem cell transplantation (HSCT) and cellular therapies in all spectrum of haematological cancers and non-malignant indications. She works in the Blood and Marrow Transplant (BMT) Unit of the IRCCS San Raffaele Hospital in Milano, Italy.

Her expertise in this field encompasses allogeneic and autologous stem cell transplantation (for malignant and non-malignant diseases), cellular therapies, immune reconstitution, biomarkers, transplant complications (i.e graft versus host disease, infections). Her career has been focused on several clinical research projects on HSCT. She has (co)authored many research articles in peer reviewed journal as well as reviews, book chapters and best-practice guidelines in the field.

She has been significantly involved with the European Group for Blood and Marrow Transplantation (EBMT), as Working Party Chair, Scientific Council Representative with the Education Portfolio, active member of the Autoimmune Diseases Working Party (ADWP) and Cellular Therapy & Immunobiology Working Party (CTIWP).

Area of expertise:

Haematology, allogeneic and autologous stem cell transplantation (for malignant and non-malignant diseases), cellular therapy and immunotherapy, immune reconstitution, transplant complications, graft versus host disease, infections in immunocompromised patients

Esra Gülderen

Bursa Uludag University | Turkey

I am a Physician-scientist at Bursa Uludag University, Turkey. After completing my MD degree with Honours at Hacettepe University, Ankara, I did my postdoctoral research in Germany and USA focusing tumour immunology and targeted therapies before starting my residency.

Carmelo Gurnari

Cleveland Clinic/Tor Vergata University USA/Italy

Claire Horgan

Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust | United Kingdom

Claire Horgan is a senior clinical research fellow in paediatric BMT, CAR-T and stem cell gene therapy at Royal Manchester Children's Hospital, UK. She is co-founder and inaugural co-chair of the EBMT Trainee Committee.

Michael Heuser

Hannover Medical School | Germany

Chair for Molecular Therapies in Haematology.

Claire Horgan

Manchester University NHS Foundation Trust | United Kingdom

Claire Horgan is a founding member and inaugural co-chair of the EBMT Trainee Committee since it was established in January 2021. She obtained her FRCPath in 2020 and is at the end of her paediatric haematology training in the UK. She is currently based in Manchester and is pursuing a senior clinical research fellowship in BMT, CAR-T and stem cell gene therapy.

Elif İnce

Ankara University Medical Faculty | Turkey

Prof. Elif İnce is Professor in Paediatrics and faculty at Ankara University Medical School, attending physician at the department of Paediatric Haematology and Bone Marrow Transplantation Unit since 2006. She completed her paediatric residency and paediatric haematology and oncology fellowship at Schneider Children's Hospital, New York, USA. She completed a one-year Pediatric Bone Marrow Transplantation Fellowship at Columbia University, New York, USA. Her practice and research areas are paediatric hematopoietic stem cell transplantation, hemoglobinopathies, congenital aplastic anaemias and coagulation. She is currently the co-chair of the Paediatric Infectious Diseases subcommittee of the EBMT Paediatric Working Party.

Michelle Kenyon

Kings College Hospital | United Kingdom

Michelle is a Consultant Nurse in Blood and Marrow Transplant (BMT) at King's College Hospital in London UK, with interests focused on improving the patient and caregiver experience of hematopoietic stem cell transplantation and supporting patients throughout their post-transplant recovery. Her research and service development interests centre on patient experience, psychosocial issues, treatment consequences, and the unmet needs of those living with and beyond their diagnosis. Her role also enables her to lead a team and teach regularly. As current President of the EBMT (European Blood and Marrow Transplant) Nurses' Group, she has a strong commitment to delivering nurse education across Europe and beyond to benefit patient care and to increase the reach and impact of the activities of the EBMT Nurses Group and EBMT Society more generally. She has authored two patient information books, which are used as the basis of informed consent for transplant recipients throughout the UK, and co-edited the first EBMT Textbook for Nurses published in 2018.

Annika Kisch

Skåne University Hospital | Sweden

Annika has been working as a nurse in the field of haematology and stem cell transplantation since 1993, at Lund university hospital, Sweden. In 2015 she finalized her thesis, Allogeneic stem cell transplantation – Patients' and sibling donors' perspectives. Since then, she is working with nursing research, development and education at the same department at the hospital, and she is also an Associated Professor at Lund University, Department of Health Sciences, with special research interest in person centred care. Since 2018 she is a member of the Nurses Group Research Committee EBMT, and since April 2021 the chair of this committee.

Lars Kligen Gjærde

Rigshospitalet | Denmark

Nicolaus-Martin Kröger

University Hospital Hamburg Germany

Dr. Nicolaus Kröger is Professor of Medicine and Medical Director of the Department of Stem Cell Transplantation at the University Medical Center Hamburg-Eppendorf, Germany. Prof. Kröger is board certified in Haematology-Oncology and Internal Medicine.

From 2018 to 2022 he was President of the European Society of Blood and Marrow Transplantation (EBMT). He served also as chairman of the German Stem Cell Working Group (DAG-KBT) from 2014-2020 and is member of several editorial boards such as Blood, Haematological, Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation. He is Co-Editor of the EBMT Handbook and the EBMT/EHA CAR-T Cell Handbook and also member of numerous Scientific Committees such as ASH, EHA, and ESH.

He has received several awards for his work to date including the prestigious EBMT van Bekkum Award in 2015. In 2020 he was awarded as Doctor Honoris Causa from the University Belgrade.

Prof. Kröger has published extensively in his area of expertise and has contributed to more than 750 publications in peer-reviewed journals such as NEJM, Lancet, JCO, JNCI, PNAS, Blood and Leukemia.

Arjan Lankester

Willem-Alexander Children's Hospital/Leiden University Medical Center | Netherlands

He is professor of Paediatrics and Stem Cell Transplantation at the University of Leiden and clinical director of the JACIE-accredited Paediatric SCT program which serves as the national centre for stem cell therapy in patients with inherited immune disorders which is full member of ERN-RITA. He has conducted and coordinated several single and multicentre investigator-initiated adoptive cellular therapy trials and is clinical PI of the multinational RECOMB RAG1-SCID gene therapy trial. He is the past chair of Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation and European Society for Immune Deficiencies.

Anita Lawitschka

St. Anna Children's Hospital, St. Anna Children Cancer Research Institute | Austria

Anita Lawitschka is a paediatric haemato-oncologist and head of the HSCT-Outpatient, Aftercare & GVHD Clinic at the St. Anna Children's Hospital, Medical University Vienna, Austria, with focuses on immune reconstitution, transplant immunology, GVHD, Late Effects and multidisciplinary networks. She has a long association with the scientific board of the EBMT PDWP currently leading the subcommittee regarding GVHD/LATE EFFECTS/QOL/AYA. She is on the panel board of the German-Austrian-Swiss GVHD Group and of the NIH-Consensus project on cGVHD 2020. In addition, she is a management committee member of the cGVHD Eurograft network. Further research interests are clinical guideline development and medical decision-making in HSCT-aftercare and GVHD with interdisciplinary research projects at the interface of clinical research and IT.

Angela Leather

The Christie | United Kingdom

Florent Malard

Hôpital Saint-Antoine, AP-HP | France

Florent Malard, MD, PhD, studied medicine at the University of Nantes, France and obtained his PhD degree at the University Pierre et Marie Curie in Paris, France, followed by a postdoctoral fellowship at the Memorial Sloan Kettering Cancer Center, New York, USA. He is now appointed as an Associate Professor at Saint-Antoine Hospital, Paris, France. His research works focused on allogeneic stem-cell transplantation, immunology, microbiota and multiple myeloma. He has published so far over 100 publications on these topics.

Alexandra Patricia Martínez Roca

Hospital Clínic de Barcelona | Spain

Dr. Alexandra Martínez-Roca is a Haematologist specialist with a master's degree in bone marrow transplantation, and a PhD student at Universitat de Barcelona. She currently works as an attending at the Haematology At Home Unit at Hospital Clínic de Barcelona where she specializes in the at-home management of acute myeloid leukaemia, CAR-T cell therapy, and autologous bone marrow transplantation.

Neema Mayor

Anthony Nolan, London | United Kingdom

Head of Immunogenetics Research at Anthony Nolan

Donal Mclornan

University College Hospital London | United Kingdom

Donal works as a Consultant in the Allogeneic transplant and CAR-T team at University College London Hospital, which has the largest transplant program in the UK. He is the current chair of the Chronic Malignancy Working Party of EBMT and leads the UK NCRI MPN group. He has special interests in MF allo-HCT and immune dysregulation in MPN.

Hilda Mekelenkamp

Leiden University Medical Center | The Netherlands

Hilda Mekelenkamp is a paediatric haematology nurse at the paediatric stem cell transplantation ward of the Leiden University Medical Centre in the Netherlands. Her research is focused on HSCT decision making for patients with hemoglobinopathies. Hilda is the chair the paediatric nurses committee and the linking nurse for the Paediatric Disease Working Party.

Mohamad Mohty

Saint-Antoine Hospital, Paris | France

Dr Mohamad Mohty is a full Professor of Haematology and head of the Haematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He obtained his medical degree from the University of Montpellier, France, and PhD from the University of Marseille, France. He is also head of a translational research team (Inserm) at the Saint-Antoine Research Centre in Paris.

Dr Mohty is the past president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukaemia Working Party of the EBMT. He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and board member of the EBMT and the Intergroupe Francophone du Myelome (IFM).

In addition to publishing more than 800 peer-reviewed articles in the field of stem cell transplantation, leukaemia, and myeloma, Dr Mohty also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International. He also serves as an editor, board member, and/or reviewer across numerous other reputable journals.

Oscar M. Pello

Blood and Tissue Bank of Cantabria – Marques de Valdecilla Foundation | Spain

Oscar M Pello received a B.Sc. on Biochemistry from the Oviedo University and a PhD in Oncolmunology from CNB-CSIC in 2006 being awarded the Outstanding PhD Award from Universidad Complutense de Madrid year 2006/07. Postdoctoral fellowships at Theleton Institute for Gene Therapy (Milan 2007/08) and Humanitas Research Institute (Milan 2008/10). In 2010 returned back to the CNIC, Spain with a Juan de la Cierva contract and as a PI of a Marie Curie Integration Grant. In 2013 moved to UCL, London as a Senior Scientist under the UCL-Research excellence Framework 2013. By the end of 2013 obtained the distinction of fellow (maximum category of the UK Institute of Biomedical Sciences) and the accreditation from the Health and Care Professional Council (HCPC-UK) to work as a Biomedical Scientist in a clinical setting and moved to the HSCT processing and Cell Therapy unit at Hammersmith Imperial NHS London. In 2018 started as a TPH processing and Cell Therapy Unit Technical Director/QP at the Blood and Tissue Bank of Cantabria – Marques de Valdecilla Foundation. He is also a JACIE inspector and member of several research and clinical associations such as the EBMT trainee committee, the JACIE Quality group or Grupo Español de Transplante Hematopoyético y Terapia Celular (GETH).

John Murray

The Christie | United Kingdom

I undertook my Registered General Nurse training in Liverpool in 1988, qualifying in 1991 and worked on the Liverpool general haematology and BMT unit for 5 years. During this time, I completed a Diploma and BSc (HONS) in Professional Health Studies finishing in 1997.

Following this I moved to work in General Medicine (Gastroenterology speciality) for 2 years; this was an invaluable experience and made my passion for haematology and transplant nursing even greater.

I travelled to Australia and worked at the Wesley BMT unit in Brisbane for 6 months, a fabulous experience of nursing in another country.

Upon my return to the UK in 2000 I completed the Marsden cancer course and then took a post as the Transplant Coordinator and Apheresis nurse at The Christie in Manchester 2001

I completed the nurse prescribing course in 2003 and with Government initiatives and the need to reduce junior doctor's hours as part of European Working Time Directive, I went on to the MSc in Advanced Practice course, qualifying in 2007.

Following my MSc I developed a new post of Nurse Clinician in BMT on the Haematology and Transplant Unit at The Christie with a special interest in GvHD and late effects of transplant.

I have been the Chair of the EBMT UK NAP group and also Chair of the EBMT scientific committee. I became the President of EBMT NG in 2017, serving for 4 years and I am now a Past President. I give regular presentations on issues related to transplantation and I have a keen interest in GvHD. Most recently I have accepted the role of co-chair of the Equality Diversity and Inclusion committee of EBMT.

Alberto Mussetti

Institut Català d'Oncologia - Hospital Duran i Reynals | Spain

I received my training in lymphomas and allogeneic transplants at the Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy). I did a clinical research fellowship at Memorial Sloan Kettering Cancer Center (New York, US) and at the CIBMTR (Milwaukee, US). I am currently directing the Transplant and Cell Therapy Unit at the Institut Català d'Oncologia. I took part in the first CART trials in Italy and Spain. I am actively collaborating with the EBMT, CIBMTR and GETH in proposing clinical studies regarding the field of immunotherapies in lymphomas. My research focus is immunotherapies for lymphomas, toxicity reduction in allogeneic transplants and digital medicine.

Arnon Nagler

Chaim Sheba Medical Center | Israel

Arnon Nagler, M.D., M.Sc., is the president of the Haemato-oncology Centre and the director of the CBB at the Chaim Sheba Medical Center, and a Professor of Medicine at The Tel Aviv University, Israel. In 2014-2018 Prof Nagler served as the Chair of the ALWP of the EBMT and is currently the Vice chair.

Benedicte Neven

Necker children hospital | France

I'm a professor of paediatrics, working in the paediatric immune-haematology Unit of Necker Children hospital in Paris. My clinical and research activities are dedicated to patients with primary immune deficiencies from diagnosis to therapy including targeted treatment when available, bone marrow transplantation and cellular therapy. I'm currently the chair of the IEWP of EBMT.

Charlotte Niemeyer

Division of Paediatric Haematology and Oncology, Department of Paediatrics, University Medical Center Freiburg | Germany

Charlotte Niemeyer, MD, graduated from the University of Freiburg in 1980. She then specialized in Paediatrics at the University of Kiel, and in Paediatric Haematology and Oncology at Boston Children's Hospital/Dana Farber Cancer Institute (1983-88), Hannover Medical School (1988-1990) and Freiburg University (since 1990). She is a Full Professor in Paediatrics and Director of the Division of Paediatric Haematology and Oncology at the Department of Paediatrics and Adolescent Medicine. Prof. Niemeyer's main scientific interest is translational research in the field of myelodysplastic syndromes in young individuals, bone marrow failure disorders and juvenile myelomonocytic leukaemia. She is a founding member of the European Working Group of MDS in Childhood (EWOG-MDS) and chairs the Coordinating Study Center of this group at her institution. With her research group, she contributed to the identification and description of genetic syndromes with a predisposition to myeloid neoplasia and to the identification of effective treatments. She received a number of honours including the election to the German Academy of Sciences Leopoldia (2010), the Deutscher Krebspreis (2021), and the Jean Bernard Lifetime Achievement Award by the European Hematology Association (2018).

Maddalena Noviello

IRCCS Ospedale San Raffaele | Italy

Dr. Noviello has extensive experience in patient immunomonitoring, she is an analytical project manager at the Cell Therapy Immunomonitoring Lab in Ospedale San Raffaele (OSR), and she is currently analysing samples from patients receiving either allogeneic hematopoietic stem cell transplantation or CAR-T cell therapies at OSR. In particular, she analyses peripheral blood by multiparametric flow cytometry and functional assays with the aim of identifying cellular signatures associated to the response to therapy and to the development of adverse events.

The Cell Therapy Immunomonitoring Lab performs immunological assays in the context of cell and gene therapy clinical studies, including phase I clinical trials, in compliance with national regulation (Determina AIFA 809/2015; Agenzia Italiana per il Farmaco - Italian Medicines Agency), with Good Clinical Practice (GCP) and, more in detail, with Good Clinical Laboratory Practice (GCLP) principles.

Attilio Olivieri

Università Politecnica delle Marche | Italy

Attilio Olivieri is an expert in stem cell transplant and cell processing. From 2006 to 2011 Responsible for the National Autologous Transplant Network (GITMO) and since 2015 Chairman of GITMO for GVHD management. In the 2014 and 2021 member of the NIH Board for the new Consensus Conference on cGVHD- Author of more than 200 peer-reviewed full papers.

Valentín Ortiz Maldonado

Hospital Clínic de Barcelona | Spain

Graduated in medicine from the Universidad Nacional de Cuyo, Argentina (2012). Specialized in haematology and hemotherapy at the Hospital Clínic de Barcelona (2017). Master's degree in hematopoietic transplantation by the Universidad de Valencia (2017) and a title of expert in Immuno-Oncology by the Universidad de Navarra (2019). Since 2017, working in the development and implementation of the CAR T-cell program for malignant hemopathies at the Hospital Clínic de Barcelona.

Christien Oudbier

Universitair Medisch Centrum Utrecht | The Netherlands

Alfonso Parisi

I.R.C.C.S. Istituto Nazionale dei Tumori | Italia

Conditioning therapy in haematopoietic stem cell transplant (HSCT) is central to the preparation or 'conditioning' the patient for the transplant. Prior to haematopoietic stem cell transplant (HSCT), the conditioning therapy is used for eradicating the disease, creating the space for engraftment and immunosuppression. The aim of conditioning regimens is to reduce relapse and rejection and can be fine-tuned to reduce treatment-related mortality. This can be done with 'reduced intensity' or non-myeloablative regimens which are less toxic or with myeloablative regimens which are a higher dose to wipe out or 'ablate' the marrow. The chemotherapy drugs are classified according to their action: alkylating agents, antimetabolites, antitumor antibiotics, plant alkaloids. The modes of administration of this cytotoxic therapy is: intravenous, subcutaneous, oral and intrathecal. TBI (total body irradiation) is used in conditioning regimens: myeloablative, reduced myeloablative and non-myeloablative. The TBI's role is twofold: suppressing the immune system of the recipient to prevent the rejection of donor marrow; eradicate the neoplastic cells that residue from chemotherapy treatments, TBI is able to target sanctuary sites such as CNS and gonads, where drugs cannot reach. The conditioning toxicities are: mucositis of the oral cavity and gastrointestinal tract, nausea and vomit, diarrhea, malnutrition, bacterial infection, viral reactivations. The patient assessment for a transplant procedure is complex and includes several factors such as the patient's overall health and performance status, comorbidities, disease risk/status (e.g., remission state and responsiveness to treatment) and graft and donor source. The autologous cell stem is indicated for the Burkitt's Lymphoma in first remission/ first greater relapse, sensitive. Hodgkin lymphoma primary refractory, sensitive/first relapse, sensitive/second greater relapse, Multiple myeloma. The allogeneic bone marrow transplant is indicated for the Acute myeloid leukaemia, acute lymphoblastic leukaemia, T-cell non-Hodgkin lymphoma, lymphoblastic B-cell non-Hodgkin lymphoma (non Burkitt).

Régis Peffault de Latour

Saint-Louis Hospital, AP-HP, Paris | France

Pr. Peffault de Latour is currently the head of the Haematology and Bone Marrow Transplant Department, Hôpital Saint-Louis, Paris, France. He is the principal investigator of numerous research studies on BMT / SAA and PNH and the author of 300 papers quoted in PubMed.

Olaf Penack

Charité, Berlin | Germany

Prof. Olaf Penack (M) is Director of the Advanced Cellular Therapy Program in the department of Haematology, Oncology and Tumorimmunology at the Charité Universitätsmedizin Berlin, Campus Virchow Clinic. His aim is to improve outcome of cellular therapies by optimized clinical management as well as by development of novel therapeutic approaches.

Zinaida Peric

School of Medicine, University of Zagreb and University Hospital Centre Zagreb

Zinaida Peric is a haematologist at the University Hospital Centre Zagreb and Assistant Professor at the School of Medicine, University of Zagreb, Croatia. Dr Peric's research activity is focused on the immunobiology of graft-vs-host disease and the role of gut microbiota in the pathogenesis of intestinal GVHD. Her clinical interests focus on acute leukaemias and infectious and long-term complications after allogeneic stem cell transplantation. Dr Peric is the Chair of the Transplant Complications Working Party and Co-leader of ALL subcommittee (Acute Leukaemia Working Party) of the European Group for Blood and Marrow Transplantation (EBMT).

Christine Peters

St. Anna Children's Hospital, Children Cancer Research Institute | Austria

Christina Peters is Professor of Paediatrics at the Department of Stem Cell Transplantation of St. Anna Children's Hospital in Vienna. Her research interests include allogeneic haematopoietic transplantation in children and adolescents with malignant and non-malignant diseases from related and unrelated donors, infectious and toxic complications after stem cell transplantation, adoptive therapies for haematological malignancies and family-oriented rehabilitation for children with life-threatening diseases. She is the international study chair of the multinational trial investigating the role of TBI vs. Chemo-conditioning in children and adolescents with ALL ("FORUM"). As an expert speaker, Dr. Peters has presented on a variety of topics at many symposia, meetings and seminars. She has authored and co-authored numerous papers in peer-review journals such as Lancet, New England Journal of Medicines, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation, Blood, Vox Sanguinis, Leukemia, Haematologica, British Journal of Haematology, and Frontiers. Prof. Peters is a member of many professional societies including IBFM, CIBMTR, EHA and SIOP. Furthermore, Dr. Peters is a member of the Advisory Board of the Austrian Ministry of Health, the Bioethical committee of the Austrian Prime Minister and a member of the ENPREMA (European Network Paediatric Research at EMA).

Jose Luis Piñana

Hospital Clínico Universitario de Valencia | Spain

Dr. Jose Luis Piñana specialized in Haematology and hemotherapy at the Hospital de la Santa Creu i Sant Pau in Barcelona. After the completion of his training, he obtained a grant from the Carlos III National Health Institute research whose main objective was the study and analysis of infectious and non-infectious complications after allogeneic hematopoietic stem cell transplantation. After completing a 1-year intensive transplant program at the Seattle Cancer Care Alliance and Fred Hutchinson Research Center, Seattle, USA, Dr Piñana continued his scientific work in the area of transplantation at the Hospital clínico Universitario of Valencia, Spain. As a result of his scientific work, Dr. Piñana continues to carry out clinical research and publish scientific works in this area. The main focus of interest includes infections after transplantation, in particular respiratory virus infections.

Marijke Quaghebeur

University Hospital Gent, Belgium

Safe cell infusion: important nursing considerations

Since 2010 working as a clinical nurse specialist in the haematology and stem cell transplant unit at in the University Hospital Ghent. Patient education, teaching junior nurses and students are part of her job. Involved in the EBMT Scientific nursing committee and board member of the nursing group from the national Belgian Haematological Society (BHS). Special interests: HSCT, adolescents and young adults with haematological diseases, patient empowerment...

Vera Radici

ASST Spedali Civili di Brescia | Italy

Young Italian haematologist with training carried out between Udine (Italy) and Saint Antoine Hospital in Paris with Prof. Mohty's team. Passionate about haematology, particularly in the field of allogeneic stem cell transplantation and cell therapies. Deeply interested in infections and long-term complications after transplant. Proud member of the EBMT trainee committee since 2020.

Alexandros Rampotas

University College London Hospitals | United Kingdom

I qualified as a doctor in Greece. Shortly afterwards I started my speciality training in the UK and was awarded an Academic Haematology Training Fellowship in Oxford. Following that I obtained a Medical Research Council Clinical Research Training Fellowship which will allow me to conduct translational research for 3 years. I have undertaken this post at University College London, Cancer Institute. My clinical work is based on University College London Hospitals. My research is focused on Myelofibrosis and Cellular therapies. I have been involved and led multiple real-world clinical studies and have been a sub-investigator in numerous clinical trials.

Laura Ricketts

University Hospital of Wales | United Kingdom

Annalisa Ruggeri

IRCCS San Raffaele scientific institute | Italy

Annalisa Ruggeri received her Medical degree from University of Messina, Italy, in 2004. She completed her Haematology residency at the San Raffaele Vita-Salute University, Milano, Italy in 2008, and the PhD in Haematology in 2014.

In 2007 she was awarded the EBMT-AMGEN fellowship at the Hospital Saint Louis in Paris, France. She was staff member at the Haematology Department at the Saint Antoine Hospital in Paris, France and at Paediatric Haemato-oncology and cell and Gene therapy Department at the Ospedale Bambino Gesù in Roma, Italy.

Since February 2020 she is senior physician at the Haematology and Bone Marrow Transplant unit of the San Raffaele Scientific Institute in Milano, Italy. Focus of research is mainly on results and risk factors of alternative donor transplants, haploidentical and cord blood transplantation, GVHD, use of cellular therapy and targeted therapy. She is active in clinical research activities being the scientific chair of the Eurocord office in Paris since 2012, and the current chair of the Cellular therapy and Immunobiology working party of the European society of Blood and Marrow transplantation (EBMT) since 2022. She is member of the ISCT- Stem cell source and graft engineering Committee. She is author of more than 200 peer-reviewed publications (H-index 45, Scopus 2022) and has participated as invited speaker of many international conferences such American Society of Hematology (educational sessions), European society of Haematology and EBMT, ESH, ISCT, TCT.

Julia Ruiz

Niño Jesus Children's' Hospital | Spain

Julia Ruiz works as Head nurse and Quality Manager of the Oncology-Haematology and Bone Marrow Transplant Unit Niño Jesús Children's' Hospital in Madrid. Her recent background is leading a LTFU Nurse consultant. She is a paediatric nurse and obtained master's degree in Hematopoietic Stem Cell Transplant by the University of Valencia. Julia is the nurse representative and nurse coordinator of the Spanish Nurses Group included in Spanish Society of Hematopoietic stem cell Transplantation (GETH). She is JACIE Inspector for Quality Management and chair of the EBMT Nurses' Global Educational Committee.

Hanno Tapani Ruutu

Clinical Research Institute, Helsinki University Hospital | Finland

Former head of the Helsinki haematopoietic stem cell transplantation unit for adults and chair of the early transplant complications subcommittee of the Transplant Complications Working Party, EBMT

Riccardo Saccardi

Careggi University Hospital | Italy

Riccardo Saccardi is a haematologist and currently Director of the Cellular Therapies and Transfusion Medicine Department at Careggi University Hospital in Florence, Italy. His scientific activity has been aimed at developing clinical research in the field of HSCT for severe Autoimmune Diseases and he has promoted national and international studies in this area. Other aspects of his scientific activity are cell manipulation for transplantation and pre-clinical and clinical experimental activity in the use of Progenitor Cells in regenerative medicine. He served as Chairman of the Autoimmune Diseases Working Party of the EBMT for two mandates, was more recently, JACIE Medical Director from 2016 to 2020 and is actively involved in the EBMT Benchmarking project. He is co-author of over 180 publications in indexed journals.

Sandra Schönfeld

Bern University of Applied Sciences | Switzerland

Sandra Schoenfeld works as a lecturer at the University of applied Sciences in Bern. Before this, she worked as a Clinical Nurse Specialist at the University Hospital in Basel at the inpatient ward with the focus on stem cell transplantation and its complications. She made her Master of Science in Nursing at the University in Basel in 2014 with the main focus on medication adherence.

Yasmina Serroukh

Erasmus MC Rotterdam | The Netherlands

Yasmina Serroukh is a Belgian board-certified clinical haematologist, currently working in Erasmus MC Cancer centre in Rotterdam, The Netherlands. She was trained in UZ Leuven and further specialized in cellular therapy in Université de Montreal - hôpital Maisonneuve-Rosemont. Yasmina Serroukh also has a strong background in fundamental immunology with a research work on cytotoxic CD4 T cells and a PhD degree from Université Libre de Bruxelles. Her main interests are lymphoproliferative disorders, and cellular immunotherapy including CAR-T cell therapy and bone marrow transplant.

Jan Styczynski

Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz | Poland

Prof. Jan Styczynski is affiliated with Department of Paediatric Haematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. Chairman of Infectious Diseases Working Party (IDWP) of European Society for Blood and Marrow Transplantation (EBMT) from 2016-2020 and Member of EBMT Scientific Committee. Vice-President of ECIL (European Conference on Infections in Leukemia). Chairman of Infectious Diseases Working Group in Polish Society of Paediatric Haematology and Oncology. National Consultant in paediatric haematology and oncology. Editor-in-Chief of Acta Haematologica Polonica, journal of Polish Society of Haematology and Blood Transfusion. Author of over 400 papers published in peer-reviewed national and international journals.

Anna Sureda

Hematology Department, Institut Català d'Oncologia, IDIBELL, Universitat de Barcelona, Barcelona | Spain

Anna Sureda, (MD, PhD) is nowadays the Head of the Clinical Hematology Department of Institut Català d'Oncologia – Hospitalet, Barcelona. She had previously been a Senior Consultant in Hospital de la Santa Creu i Sant Pau, Barcelona (from January 1991 to December 2010) and a Senior Consultant focused in lymphomas and hematopoietic stem cell transplantation (HSCT) at Addenbrookes–Cambridge University Hospital, UK (December 2010 – December 2012). Anna Sureda has focused her career on clinical investigations into the treatment of Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma patients evaluating novel therapies such as immunotherapy combined with stem-cell transplantation. Anna Sureda was appointed Chairperson of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT) from March 2004 to March 2010 and Secretary of the same organization from March 2010 to March 2016. She was elected co-chair of the Lymphoma Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) and has served the organization in this position from February 2015 to February 2019. She was subsequently appointed as member of a large non-US Transplant Center in the Advisory Committee of the CIBMTR (from February 2019). In March 2021, Anna Sureda was elected President Elect of the EBMT.

Richard Towers

Kings College Hospital England

Palliative care Symptom management and Advance care planning
Nurse Consultant in palliative care working in the Cicely Saunders Institute for palliative care at Kings College Hospital London.

Eugenia Trigo

Hospital Universitario y Politécnico La Fe, Valencia | Spain

I'm a specialist paediatric nurse with several years of experience in paediatric haematological transplant units. I'm also a lecturer at the Faculty of Medicine and Health Sciences at the University of Barcelona and an Associate Professor at the Facultad de Enfermería y Podología in Valencia. I collaborate on the paediatric nurses training course at the European University of Valencia. I have also been an active participant in the Paediatric Disease Working Party Meetings and international training courses for nurses and young doctors in Jerusalem, Rhodes, Bucharest and Marrakech.

I have an extensive experience as a quality management inspector and have been an active member of the Inspectors Committee during the first 18 months of the Inspectors Committee. I have also been working with the EBMT in a number of roles including a local nurse for the Annual Meeting in Valencia in 2016 and chairing the Nurses Global Education Committee.

Dominik Turkiewicz

Childhood Cancer Center, University Hospital in Scania, Lund | Sweden

MD, PhD Dominik Turkiewicz is Clinical Director of the Paediatric Stem Cell Transplantation program at University Hospital in Lund. Current research focuses on AML, MDS/SAA/IBMFS and hemoglobinopathies, haploidentical HSCT and other cellular and immunotherapies as well as the application of statistics in design and execution of randomized clinical trials.

Luca Vago

IRCCS San Raffaele Scientific Institute | Italy

Prof. Luca Vago is a physician-scientist, and both his clinical and research activities are focused on elucidating the interplay between the immune system and leukaemia, especially in the model system of allogeneic HCT. In particular, his group's research focuses on the understanding mechanism by which post-transplantation relapses occur, combining cutting-edge immunogenomic analysis of patient samples with the development of innovative humanized animal models. His long-term aim is to develop personalized therapeutic approaches able to rewire a proficient graft-versus-tumour effect.

Robert Wynn

Royal Manchester Children's Hospital | United Kingdom

Rob Wynn is Director of the Blood and Marrow Transplant (BMT) Unit in the Royal Manchester Children's Hospital and Honorary Professor of Clinical Paediatric Haematology and Cellular Therapy. He grew up in Liverpool and undergraduate medical training was undertaken in Cambridge and The London, post graduate training in Newcastle and Edinburgh and Haematology and Transplant training in Manchester and Toronto. He is also an avid Liverpool fan!

Manchester has a specific interest and expertise in the transplant of children with metabolic disorders. Manchester has also developed an expertise in cord blood transplant in both malignant and non-malignant disease in children, and this recognition of the utility of this cell source in specific clinical situations is being explored in ongoing research activities of our programme.

The success of allogeneic cellular therapy in some disorders has recently led to a re-appraisal of gene therapy for currently treatment-refractory disorders, and we have pioneered, including first-in-world therapies, stem cell gene therapy of metabolic diseases.

The BMT Unit and its practice and development in this field have been enormously influenced by the late Professor Ed Wraith, a true pioneer in this field. Rob has over 200 papers, has authored several chapters and textbooks in the Haematology and BMT fields and often talks to audiences of different backgrounds on these topics.

Alienor Xhaard

Hôpital Saint Louis | France

Ibrahim Yakoub-Agha

CHU de Lille | France

Current chair of the practice harmonization and guidelines of the EBMT. Prof. Ibrahim Yakoub-Agha has served as Head of the Hematopoietic Cell Transplantation Unit at Lille University Hospital since 2008. He is also Editor in Chief of Current Research in Translational Medicine and has co-authored more than 460 scientific articles.

Marco Zecca

Fondazione IRCCS Policlinico San Matteo | Italy

Marco Zecca M.D. is the Director of the Pediatric Haematology/Oncology and of the Hematopoietic Stem Cell Transplant Programme at the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, and Contract Professor, Medical School, University of Pavia.

He received his M.D. degree at the University of Pavia, and completed his medical training for specialization in Paediatrics and Paediatric Haematology/Oncology under the mentorship of Prof. Franco Locatelli at Fondazione IRCCS Policlinico San Matteo, Pavia.

His clinical and research interests have focused on strategies to improve the outcome of allogeneic HSCT for malignant and non-malignant paediatric haematological disorders, including the design of novel conditioning regimens, prevention/treatment of graft-versus-host disease, infectious complications and VOD, and the diagnosis and treatment of myelodysplastic syndromes in paediatric patients.

He has coordinated the Study Group on Myelodysplastic Syndromes of the Italian Association of Paediatric Haematology and Oncology (AIEOP) and has been a national coordinator within the European Working Group on Myelodysplastic Syndromes in Childhood. His current research interests include applications of cell therapy in transplantation and haematology/oncology.

Dr. Zecca is Past-President of AIEOP, and a member of the European Group for Blood and Marrow Transplantation (EBMT). He serves as Faculty Member in the Master Courses in Paediatric Haematology organized by the University "La Sapienza", Rome, and in Paediatric Immunology organized by the University of Pavia.